Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APOP
CUSIPN/A
Phone972-9974-1444
Debt
Debt-to-Equity RatioN/A
Current Ratio11.07
Quick Ratio11.07
Price-To-Earnings
Trailing P/E Ratio-5.03
Forward P/E Ratio-7.35
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book7.35
Profitability
EPS (Most Recent Fiscal Year)($1.46)
Net Income$-8,140,000.00
Net MarginsN/A
Return on Equity-93.41%
Return on Assets-59.62%
Miscellaneous
Employees24
Outstanding Shares5,440,000
Market Cap$39.98
CELLECT BIOTECH/S (NASDAQ:APOP) Frequently Asked Questions
What is CELLECT BIOTECH/S's stock symbol?
CELLECT BIOTECH/S trades on the NASDAQ under the ticker symbol "APOP."
How were CELLECT BIOTECH/S's earnings last quarter?
CELLECT BIOTECH/S (NASDAQ:APOP) posted its quarterly earnings results on Thursday, May, 17th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.14. View CELLECT BIOTECH/S's Earnings History.
When is CELLECT BIOTECH/S's next earnings date?
What price target have analysts set for APOP?
1 equities research analysts have issued twelve-month price targets for CELLECT BIOTECH/S's shares. Their predictions range from $14.00 to $14.00. On average, they anticipate CELLECT BIOTECH/S's stock price to reach $14.00 in the next year. This suggests a possible upside of 90.5% from the stock's current price. View Analyst Ratings for CELLECT BIOTECH/S.
What is the consensus analysts' recommendation for CELLECT BIOTECH/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELLECT BIOTECH/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about CELLECT BIOTECH/S stock?
Here are some recent quotes from research analysts about CELLECT BIOTECH/S stock:
- 1. According to Zacks Investment Research, "Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel. " (5/31/2018)
- 2. HC Wainwright analysts commented, "We continue to expect that this cushion should be sufficient to fund operations through 2019. The January 2018 financing included unregistered warrants with an exercise price of $12.00 per ADS, which could if exercised in full accrue an additional $3.2M to the company. Assuming Cellect remains capital- efficient and warrant exercises proceed as projected, we believe the company could continue to operate well into 2020 without requiring further capital to be raised. R&D expenses were slightly below our projection at $0.8M vs. $1M, while G&A spending was somewhat above our estimate at roughly $1M vs. $0.9M. The company recorded a net loss of only $0.16 per share vs. our projection of $0.30 per share, primarily due to the favorable impact of about $0.8M in financial non- cash items." (5/29/2018)
Who are some of CELLECT BIOTECH/S's key competitors?
Some companies that are related to CELLECT BIOTECH/S include Apollo Endosurgery (APEN), Motus GI (MOTS), Sensus Healthcare (SRTS), Invuity (IVTY), Restoration Robotics (HAIR), Alphatec (ATEC), Invo Bioscience (IVOB), Neovasc (NVCN), Arch Therapeutics (ARTH), Spectral Medical (EDTXF), CAS Medical Systems (CASM), SANUWAVE Health, Inc. Common Stock (SNWV), iCAD (ICAD), Repro-Med Systems (REPR) and Nephros (NEPH).
Who are CELLECT BIOTECH/S's key executives?
CELLECT BIOTECH/S's management team includes the folowing people:
- Mr. Kasbian Nuriel Chirich, Co-Founder & Exec. Chairman (Age 60)
- Dr. Shai Yarkoni, Co-Founder, CEO & Director (Age 60)
- Dr. Nadir Askenasy M.D., Ph.D., Co-Founder and Chief Scientist (Age 59)
- Dr. Amotz Nechushtan Ph.D., VP of R&D (Age 58)
- Mr. Eyal Leibovitz, CFO & Principal Accounting Officer (Age 57)
Has CELLECT BIOTECH/S been receiving favorable news coverage?
Media stories about APOP stock have been trending somewhat positive on Monday, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CELLECT BIOTECH/S earned a coverage optimism score of 0.10 on Accern's scale. They also assigned news articles about the company an impact score of 46.11 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of CELLECT BIOTECH/S?
Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELLECT BIOTECH/S's stock price today?
One share of APOP stock can currently be purchased for approximately $7.35.
How big of a company is CELLECT BIOTECH/S?
CELLECT BIOTECH/S has a market capitalization of $39.98 million. The company earns $-8,140,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. CELLECT BIOTECH/S employs 24 workers across the globe.
How can I contact CELLECT BIOTECH/S?
CELLECT BIOTECH/S's mailing address is 23 Hata'as Street, Kfar Saba L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected]
MarketBeat Community Rating for CELLECT BIOTECH/S (NASDAQ APOP)
MarketBeat's community ratings are surveys of what our community members think about CELLECT BIOTECH/S and other stocks. Vote "Outperform" if you believe APOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
